# US 2026/0061031 A1 · Methods and pharmaceutical compositions for the treatment of dilated cardiomyopathy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0061031 A1
- Document ID: US20260061031A1
- Status: Published application
- Kind: A1
- Application number: 19/105,235
- Filed: 2023-09-13
- Published: 2026-03-05
- Earliest claimed: 2022-09-14
- Assignees: Institut National de la Sante et de la Recherche Medicale; Universite De Rouen Normandie
- Applicants: Institut National De La Santé Et De La Recherche MéDicale; Université De Rouen Normandie
- Inventors: Sahil ADRIOUCHI; Theo LEMARCIS; Virginie TARDIF SAN MARTIN
- Web page: https://patentgrep.com/patent/US20260061031A1

## CPC

- A61K 38/1774: {Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)}
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- G01N 33/5023: {on expression patterns}
- G01N 2333/70521: CD28, CD152
- G01N 2500/04: Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Co-signaling immunotherapy, via immune checkpoint inhibitors (ICIs), such as ipilimumab (anti-CTLA-4) or nivolumab (anti-PD-1), has revolutionized cancer treatment. However, reinvigorating tumor-infiltrating T cell cytotoxicity has revealed cardiac toxicity in a subset of patients. The inventors found lower transcriptomic expression of CTLA-4 in eccentric hypertrophic cardiomyopathy model, associated with higher cardiac total IgG amount and less B cell infiltration, compared to concentric hypertrophic cardiomyopathy. The present invention relates to a method of treating dilated cardiomyopathy (DCM) in a subject in need thereof comprising a step of administering to said subject a therapeutically effective amount of a cytotoxic T-lymphocyte-associated protein (CTLA-4) molecule.

## Claims

### Claim 1

A method of treating dilated cardiomyopathy (DCM) in a subject in need thereof comprising a step of administering to said subject a therapeutically effective amount of a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) molecule.

### Claim 2 (depends on 1)

The method of claim 1 wherein the molecule of CTLA-4 is a small organic molecule.

### Claim 3 (depends on 1)

The method of claim 1 wherein the molecule of CTLA-4 is abatacept.

### Claim 4 (depends on 1)

The method of claim 1 wherein the molecule of CTLA-4 is belatacept.

### Claim 5 (depends on 1)

The method of claim 1 wherein the molecule of CTLA-4 is combined with radiation therapy.

### Claim 6 (depends on 1)

The method of claim 1 wherein the molecule of CTLA-4 is combined with immunotherapy.

### Claim 7 (depends on 1)

The method of claim 1 wherein the molecule of CTLA-4 is combined with chemotherapy.

### Claim 8 (depends on 1)

The method of claim 1 wherein the molecule of CTLA-4 is combined with an anti-fibrotic agent.

### Claim 9 (depends on 1)

The method of claim 1 wherein the molecule of CTLA-4 is combined with an anti-TNF receptor family.

### Claim 10 (depends on 1)

The method of claim 1 wherein the molecule of CTLA-4 is combined with anti-a proliferation-inducing ligand (APRIL).

### Claim 11 (depends on 1)

The method of claim 1 wherein the molecule of CTLA-4 is combined with anti-Osteoprotegerin (OPG).

### Claim 12

A method for modulating cardiac remodeling in a subject in need thereof comprising a step of administering to said subject a therapeutically effective amount of a cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) molecule.

### Claim 13

A pharmaceutical composition comprising a molecule of CTLA-4.

### Claim 14

A method of screening a drug suitable for treating dilated cardiomyopathy (DCM) comprising i) providing a test compound and ii) determining the ability of said test compound to activate the expression or activity of CTLA-4.
